You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Diabetes Articles
Popular Diabetes Articles
Highly Recommended Diabetes Articles
Send a link to this page to your friends and colleagues.
On May 10, Generex Biotechnology Corp. of Toronto announced it has commenced long-term, phase II clinical trials of its oral insulin. The trials will be conducted in people with type 1 and type 2 diabetes.
The trials will test the safety and efficacy of the oral insulin formulation for a minimum of six months. Specifically, these trials will involve the use of the oral insulin formulation to:
Administered as a Spray into the Mouth
Generex's oral insulin is administered as a fine spray into the mouth via RapidMist-a small device that looks like an asthma inhaler.
According to Generex, there are currently 10 clinical sites in the United States, five sites in Canada and three sites in Europe participating in the long-term trials using the oral insulin formulation. Among these sites are The Diabetes and Glandular Disease Clinic of San Antonio, Texas and The National Research Institute of Los Angeles.
"We believe these long-term trials will demonstrate the positive benefits of oral insulin in helping type 1 and type 2 diabetics in achieving better control of this devastating disease," said Dr. Pankaj Modi, Generex's vice president of research. "Significantly, oral insulin will have an impact in the treatment of type 2 patients who are failing tablet therapy, since use of the oral insulin formulation will prevent the otherwise necessary insulin injection therapy."
0 comments - Jan 7, 2000
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.